114 related articles for article (PubMed ID: 37371624)
1. Controlled Attenuation Parameter Is Associated with a Distinct Systemic Inflammatory Milieu after Clearance of HCV Infection.
Du Y; Khera T; Liu Z; Tudrujek-Zdunek M; Dworzanska A; Cornberg M; Xu CJ; Tomasiewicz K; Wedemeyer H
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371624
[TBL] [Abstract][Full Text] [Related]
2. Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter.
Shimizu K; Soroida Y; Sato M; Hikita H; Kobayashi T; Endo M; Sato M; Gotoh H; Iwai T; Tateishi R; Koike K; Yatomi Y; Ikeda H
Sci Rep; 2018 May; 8(1):7845. PubMed ID: 29777191
[TBL] [Abstract][Full Text] [Related]
3. The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection.
Johnson LP; Sterling RK
Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32344543
[TBL] [Abstract][Full Text] [Related]
4. Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.
Trifan A; Stratina E; Rotaru A; Stafie R; Zenovia S; Nastasa R; Huiban L; Sfarti C; Cojocariu C; Cuciureanu T; Muzica C; Chiriac S; Girleanu I; Singeap AM; Stanciu C
Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328255
[TBL] [Abstract][Full Text] [Related]
5. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
[TBL] [Abstract][Full Text] [Related]
6. Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C.
Hengst J; Falk CS; Schlaphoff V; Deterding K; Manns MP; Cornberg M; Wedemeyer H
J Infect Dis; 2016 Dec; 214(12):1965-1974. PubMed ID: 27683821
[TBL] [Abstract][Full Text] [Related]
7. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP).
Cespiati A; Petta S; Lombardi R; Di Marco V; Calvaruso V; Bertelli C; Pisano G; Fatta E; Sigon G; Iuculano F; Crapanzano L; Gibilaro G; Francione P; Craxì A; Fargion S; Fracanzani AL
Dig Liver Dis; 2021 Oct; 53(10):1301-1307. PubMed ID: 33214063
[TBL] [Abstract][Full Text] [Related]
8. Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography.
Rout G; Nayak B; Patel AH; Gunjan D; Singh V; Kedia S; Shalimar
J Clin Exp Hepatol; 2019; 9(2):207-214. PubMed ID: 31024203
[TBL] [Abstract][Full Text] [Related]
9. Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance.
Aregay A; Engel B; Port K; Vondran FWR; Bremer B; Niehaus C; Khera T; Richter N; Jaeckel E; Cornberg M; Taubert R; Wedemeyer H
Liver Transpl; 2021 Jun; 27(6):887-899. PubMed ID: 33641215
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication.
Chromy D; Mandorfer M; Bucsics T; Schwabl P; Bauer D; Scheiner B; Schmidbauer C; Lang GF; Szekeres T; Ferenci P; Trauner M; Reiberger T
AIDS Patient Care STDS; 2019 May; 33(5):197-206. PubMed ID: 31067123
[TBL] [Abstract][Full Text] [Related]
11. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication.
Biagi F; Carlomagno F; Carbone M; Veralli R; Vespasiani-Gentilucci U; Riva E; Manfrini S; Tuccinardi D; De Santis A; Gnessi L; Watanabe M
Metabolites; 2023 Oct; 13(11):. PubMed ID: 37999215
[TBL] [Abstract][Full Text] [Related]
13. Steatosis Rates by Liver Biopsy and Transient Elastography With Controlled Attenuation Parameter in Clinical Experience of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus/HCV Coinfection in a Large US Hepatitis Clinic.
Sansom SE; Martin J; Adeyemi O; Burke K; Winston C; Markham S; Go B; Huhn G
Open Forum Infect Dis; 2019 Apr; 6(4):ofz099. PubMed ID: 30968054
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
15. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients.
Shen F; Zheng RD; Mi YQ; Wang XY; Pan Q; Chen GY; Cao HX; Chen ML; Xu L; Chen JN; Cao Y; Zhang RN; Xu LM; Fan JG
World J Gastroenterol; 2014 Apr; 20(16):4702-11. PubMed ID: 24782622
[TBL] [Abstract][Full Text] [Related]
16. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
17. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
[TBL] [Abstract][Full Text] [Related]
19. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Hamdane N; Jühling F; Crouchet E; El Saghire H; Thumann C; Oudot MA; Bandiera S; Saviano A; Ponsolles C; Roca Suarez AA; Li S; Fujiwara N; Ono A; Davidson I; Bardeesy N; Schmidl C; Bock C; Schuster C; Lupberger J; Habersetzer F; Doffoël M; Piardi T; Sommacale D; Imamura M; Uchida T; Ohdan H; Aikata H; Chayama K; Boldanova T; Pessaux P; Fuchs BC; Hoshida Y; Zeisel MB; Duong FHT; Baumert TF
Gastroenterology; 2019 Jun; 156(8):2313-2329.e7. PubMed ID: 30836093
[TBL] [Abstract][Full Text] [Related]
20. Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis C.
Chen JY; Cheng PN; Chiu YC; Chiu HC; Tsai WC; Tsai LM
J Viral Hepat; 2021 Jan; 28(1):159-167. PubMed ID: 32929802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]